NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 22, 2011 | $185,000 | Replaced |
| 2nd Quarter - Amendment | Dec 16, 2011 | $178,134 | Replaced |
| 2nd Quarter - Amendment | Jan 23, 2015 | $178,134 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| JOHN M COSTER | — |
| ADNAN JALIL | — |
| DAVID SANDERS | — |
Small Business SMB
H.R.4, the Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011, legislation would repeal provision of the Patient Protection and Affordable Care Act (PPACA) that expanded 1099 tax reporting requirements for businesses that purchase goods and services of more than $600-became law 4/14/11; opposed Senate amendment 392 to S. 782 which would delay implementation of the of new caps on credit card fees. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| JOHN M COSTER | — |
| ADNAN JALIL | — |
| DAVID SANDERS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.